Robert GottliebPrincipal, RMG Associates
Robert, who is the Principal at the communications and strategy consulting firm, RMG Associates, has more than 30 years of experience in the biotechnology and pharmaceutical industries as a consultant on strategy and communications, in-house communications director, and journalist.
He has substantial experience and a strong track record in work with well over 150 companies and organizations ranging from start-ups, to multi-nationals to academic institutions. Robert and RMG Associates bring particular expertise in positioning, external and internal communications strategy, and preparation for financing and partnering, including business plans, presentations and other materials, and web site development. He has helped more than 20 clients develop business plans to support venture and public financings.
In collaboration with several consulting networks, Robert also works with government economic development agencies and life science companies in their regions to support their partnering, financing, and other commercial efforts in the US.
Robert co-founded Feinstein Kean Healthcare (now a division of Ogilvy Public Relations Worldwide), a Massachusetts-based communications and business consulting firm focused exclusively on biotechnology, pharmaceutical, and related healthcare organizations. Robert has been an active member of the biotechnology community in Massachusetts for more than 25 years. Robert served as an advisor to the Massachusetts Biotechnology Council board of directors for over 15 years. He also participates as a mentor in MIT’s Venture Mentoring Service and the Boston University Business School’s Health Sector mentoring program.
Previously, Robert directed press relations and corporate communications at Biogen Inc., during a period that laid the foundation for the company’s turnaround. He also managed communications for Biogen’s Research and Development Limited Partnership. Prior to Biogen, Robert was executive editor of F-D-C Reports, “The Pink Sheet,” During his ten years at “The Pink Sheet,” he covered the FDA and drug regulation, pharmaceutical business and the emergence of biotechnology as an industry. He also founded a reference publication for the pharmaceutical and biotechnology industries, The NDA Pipeline.
Robert holds a B.A. degree from Trinity College (Connecticut).